Amyloid vaccine for Alzheimer’s disease- Is it feasible?

Supreet Khare, Deeksha Seth, Shrayash Khare

Abstract


lzheimer’s disease (AD) is the most common neurodegenerative disorder and the most prevalent cause of dementia with ageing in the world. The social and economic burdens of AD continue to rise. In 2010, an estimated 36 million people worldwide were living with dementia— a number that is projected to increase to 66 million in 2030, and to 115 million in 2050.

Keywords


Alzheimer’s disease, Vaccine, β-amyloid, Immunization

Full Text:

PDF

References


Chackerian B et al (2006). Virus and virus-like particle-based immunogens for Alzheimer’s disease induce antibody responses against amyloid-β without concomitant T cell responses. Vaccine. Vol 24, Issues 37–39, pp 6321–6331.

Hock C. et al (2003). Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer’s Disease. Neuron. Vol 38, Issue 4, p547–554.

Lemere C et al (2001). Nasal Vaccination with β-Amyloid Peptide for the Treatment of Alzheimer’s Disease. DNA Cell Biology. Vol 20 Issue 20 (11) pp 705-11.

Lemere C. & Masliah E. (2010). Can Alzheimer disease be prevented by amyloid-β immunotherapy? Nature Reviews Neurology Vol 6, pp 108-119.




Bookmark and Share


Copyright (c) 2014 Supreet Khare, Deeksha Seth, Shrayash Khare

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

 

All published Articles are Open Access at  https://journals.pen2print.org/index.php/ijr/ 


Paper submission: ijr@pen2print.org